title: Maintenance phase in psoralen-ultraviolet A phototherapy of early-stage mycosis fungoides. A critically appraised topic.
abstract: A 65-year-old patient affected by mycosis fungoides (MF) stage IB achieved complete remission (CR) after a cycle of PUVA phototherapy. The U.S. Cutaneous Lymphoma Consortium (USCLC) guidelines suggest that the patient should be kept in the maintenance phase, defined as a 'period of gradual decrease of frequency of UVL [ultraviolet light] while in clinical remission before discontinuation of phototherapy' by slowly tapering the number of psoralen-ultraviolet A (PUVA) applications over time up to clinical relapse. The USCLC guidelines also suggest a standardized schedule for the maintenance phase. Alternatively, the patient could end PUVA therapy and go straight to follow-up. The aim of this critically appraised topic (CAT) was to determine if a maintenance phase gives a significant benefit in terms of relapse rate (RR) and RFI in patients affected by early-stage MF who had achieved CR under PUVA phototherapy. Embase, PubMed and TRIP databases were searched for 'mycosis fungoides' AND [('photochemotherapy' OR 'puva') OR 'psoralen'] in June 2016. Three articles matched our inclusion criteria and are discussed in this CAT. In this field of research the literature is poor and the reported level of evidence is low. Only one of the studies was conducted prospectively, and none were randomized. No significant difference in terms of reduction in relapse rate or increase in RFI in patients who underwent a PUVA maintenance phase emerged when compared with those who went for simple follow-up. Further randomized clinical trials (RCTs) are required in order to evaluate maintenance phase vs. no treatment before it can be favoured as the standard protocol of treatment in early-stage MF. At the time of writing this paper, we report an ongoing Austrian multicentre RCT (Clinical Trial.gov identifier: NCT01686594) that will hopefully give useful results in this topic.
authors.affiliation: Division of Dermatology, Department of Surgery and Translational Medicine, University of Florence Medical School, Florence, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Grandi
authors.affiliation: Division of Dermatology, Department of Surgery and Translational Medicine, University of Florence Medical School, Florence, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Delfino
authors.affiliation: Division of Dermatology, Department of Surgery and Translational Medicine, University of Florence Medical School, Florence, Italy.|Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Pileri
authors.affiliation: Division of Dermatology, Department of Surgery and Translational Medicine, University of Florence Medical School, Florence, Italy.
authors.forename: N
authors.initials: N
authors.lastname: Pimpinelli
mesh_terms: D000368:Aged; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D009182:Mycosis Fungoides / Q000188:drug therapy*; D011701:PUVA Therapy / Q000379:methods*; D016032:Randomized Controlled Trials as Topic; D012878:Skin Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome